Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in Severe, Poorly Controlled Asthma
NCT02794519Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Sirukumab with Placebo (2 arms). Primary endpoint: Change from Baseline in Asthma Control Questionnaire-7 at 24 weeks. Planned start Sep 2016; status: withdrawn.
02
Drugs
sirukumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02794519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02794519.